The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

Palvella Therapeutics is set to expand its 24-week Phase III SELVA trial to include subjects aged three to five years old for ...

除TD Cowen外，H.C. Wainwright也重申了对Palvella Therapeutics的积极立场，维持买入评级和38.00美元的目标价。该公司特别关注QTORIN rapamycin在治疗皮肤静脉畸形方面的潜力，以实现公司的销售目标。

CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...

Tech entrepreneur and longevity advocate Bryan Johnson has discontinued his use of rapamycin, a controversial anti-ageing ...

The former Silicon Valley executive said preclinical and clinical research indicated that prolonged rapamycin use can disrupt ...

Palvella Therapeutics (PVLA) announced that it will expand SELVA, the Company’s Phase 3 clinical trial of QTORIN 3.9% rapamycin anhydrous gel ...

H.C. Wainwright reaffirmed a Buy rating and a $38.00 price target for Palvella Therapeutics (NASDAQ: PVLA) shares. Currently trading at $15.72, the stock has shown strong momentum with a 31% gain year ...